Side-by-side · Research reference
GLP-1 (7-37)vsPNC-27
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticHUMAN-REVIEWED16/43 cited
BAnimal-StrongHUMAN-REVIEWED18/41 cited
GLP-1 (7-37)
Incretin Hormone · Native Peptide
Research use only · IV/SC in experimental settings
PNC-27
p53-HDM-2 Peptide · Membrane-Targeting
In vitro / Pre-clinical only
01Mechanism of Action
Parameter
GLP-1 (7-37)
PNC-27
Primary target
GLP-1 receptor (class B GPCR)Koole 2015
Membrane-bound HDM-2 protein on cancer cell surfaceSarafraz-Yazdi 2022Krzesaj 2024
Pathway
GLP-1R activation → cAMP production → PKA signaling → insulin secretion (pancreatic β-cells)Lu 2025Koole 2015
PNC-27 binds to membrane HDM-2 1-109 domain → transmembrane pore formation → rapid necrosis (poptosis)Pincus 2024Krzesaj 2024
Downstream effect
Glucose-dependent insulin release, glucagon suppression, delayed gastric emptying, reduced food intakeLu 2025Ding 2017
Immediate cell lysis and extrusion of intracellular contents; secondary mitochondrial membrane disruptionPincus 2024Krzesaj 2024
Feedback intact?
Yes — physiological secretion and degradation preserved
N/A — cytotoxic mechanism, not signaling modulation
Origin
Endogenous peptide cleaved from proglucagon in intestinal L cells; secreted postprandially
Chimeric design: p53 transactivating domain (12-26) fused to penetratin CPP sequenceSarafraz-Yazdi 2022
Antibody development
—
—
02Dosage Protocols
Parameter
GLP-1 (7-37)
PNC-27
Clinical use
None — native GLP-1 not used therapeutically
Engineered analogues (semaglutide, liraglutide) used clinically.Friedman 2024
—
Research dosing
Variable — 0.1–10 nmol/kg in animal models
Used as reference standard for analogue comparison.
—
Modified analogues
t½ extended to 13 h (liraglutide), 165 h (semaglutide)
Via DPP-4 resistance + fatty acid acylation.
—
Clinical status
—
Pre-clinical only — no human trials
In vitro and animal model data only.
In vitro concentrations
—
10–100 μM range
Effective concentrations in cell culture studies.
Shorter analogue
—
PNC-28 (28 AA variant)
Retains HDM-2 binding and cytotoxic activity.
Evidence basis
—
Pre-clinical / In vitro
03Metabolic / Fat Loss Evidence
Parameter
GLP-1 (7-37)
PNC-27
Mechanism
GLP-1R activation in hypothalamic satiety centers (arcuate nucleus) reduces food intakeLu 2025
Effect demonstrated with long-acting analogues (liraglutide).Lu 2025
—
Native GLP-1 efficacy
Minimal — rapid degradation prevents sustained appetite suppression
—
Gastric emptying
Delayed in animal models, contributing to satiety
—
Body weight impact
Not observed with native GLP-1 — requires analogue formulations
—
Fat loss mechanism
—
None — cytotoxic anticancer agent
04Side Effects & Safety
Parameter
GLP-1 (7-37)
PNC-27
Native GLP-1
Well-tolerated in research settings; no prolonged exposure data
—
Hypoglycemia risk
Low — insulin secretion is glucose-dependent
—
Analogue side effects
Nausea, vomiting, diarrhea (GLP-1R agonists)
Not applicable to native GLP-1 due to non-therapeutic use.
—
GLP-1 resistance
High glucose-induced PKCβ overexpression may reduce GLP-1 responsiveness in endothelial cellsPujadas 2016
—
Human safety data
—
None available — no human trials conducted
Normal cell selectivity
—
In vitro: no cytotoxicity to normal cells (MCF-10-2A, peripheral blood mononuclear cells)Sarafraz-Yazdi 2010Thadi 2020
Normal cells express minimal membrane HDM-2.
Cancer cell specificity
—
Depends on membrane HDM-2 expression levels
Ovarian cancer lines with low membrane HDM-2 showed <30% necrosis.
Mitochondrial effects
—
Secondary mitochondrial membrane disruption in cancer cells
Absolute Contraindications
GLP-1 (7-37)
—PNC-27
- ·Human use — no clinical trials or safety data
Relative Contraindications
GLP-1 (7-37)
—PNC-27
—05Administration Protocol
Parameter
GLP-1 (7-37)
PNC-27
1. Research use only
Native GLP-1(7-37) is not formulated for therapeutic use. Administered IV or SC in experimental protocols to study GLP-1R pharmacology and as reference standard for analogue development.
PNC-27 has not been tested in human subjects. All data derive from in vitro cancer cell line studies and limited animal models. No approved clinical formulation, dosing protocol, or safety profile exists.Pincus 2024
2. Storage
Lyophilised peptide stored at -20°C or below. Reconstituted solutions should be prepared fresh and used immediately due to rapid degradation.
In vitro studies used 10–100 μM PNC-27 dissolved in cell culture medium. Peptide was added directly to cancer cell cultures (pancreatic, breast, colon, ovarian, leukemia lines) and incubated for 24–72 hours.
3. Clinical alternatives
For therapeutic GLP-1R activation, use FDA-approved long-acting analogues: semaglutide (once weekly), liraglutide (once daily), dulaglutide (once weekly), or exenatide (twice daily or once weekly).
Dual-labeled PNC-27 (green on N-terminus, red on C-terminus) demonstrated intact peptide binding to cancer cell membranes with combined yellow fluorescence at 30 minutes, persisting during cell lysis.Sookraj 2010
4. Membrane HDM-2 requirement
—
Cytotoxicity correlates directly with membrane HDM-2 expression levels. Blocking HDM-2's p53-binding domain (1-109) with monoclonal antibodies prevents PNC-27-induced necrosis.